1. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Craig Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet L. Franklin, Jerald P. Radich, and Soheil Meshinchi Blood Volume 113(26):6558-6566 June 25, 2009 ©2009 by American Society of Hematology

2. CEBPA mutations, CCG-2941/2961 and COG-AAML03P1. Phoenix A. Ho et al. Blood 2009;113:6558-6566 ©2009 by American Society of Hematology

3. Cytogenetics and FAB class of patients with and without CEBPA mutations. Phoenix A. Ho et al. Blood 2009;113:6558-6566 ©2009 by American Society of Hematology

4. Clinical significance of CEBPA mutations in pediatric AML. Kaplan-Meier estimates for (A) overall survival and (B) event-free survival from study entry for patients with and without CEBPA mutations. Phoenix A. Ho et al. Blood 2009;113:6558-6566 ©2009 by American Society of Hematology

5. Clinical outcomes for patients with CEBPA mutations versus core binding factor AML versus neither. Phoenix A. Ho et al. Blood 2009;113:6558-6566 ©2009 by American Society of Hematology

6. Comparison of clinical outcome for patients with “single” versus “double” CEBPA mutations. Phoenix A. Ho et al. Blood 2009;113:6558-6566 ©2009 by American Society of Hematology